Show simple item record

dc.contributor.authorPorter, L
dc.contributor.authorShoushtarizadeh, A
dc.contributor.authorJelinek, GA
dc.contributor.authorBrown, CR
dc.contributor.authorLim, CK
dc.contributor.authorde Livera, AM
dc.contributor.authorJacobs, KR
dc.contributor.authorWeiland, TJ
dc.date.accessioned2021-05-03T01:46:37Z
dc.date.available2021-05-03T01:46:37Z
dc.date.issued2020-12-14
dc.identifier.citationPorter, L., Shoushtarizadeh, A., Jelinek, G. A., Brown, C. R., Lim, C. K., de Livera, A. M., Jacobs, K. R. & Weiland, T. J. (2020). Metabolomic Biomarkers of Multiple Sclerosis: A Systematic Review. FRONTIERS IN MOLECULAR BIOSCIENCES, 7, https://doi.org/10.3389/fmolb.2020.574133.
dc.identifier.issn2296-889X
dc.identifier.urihttp://hdl.handle.net/11343/272495
dc.description.abstractBackground: Magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, and the McDonald's clinical criteria are currently utilized tools in diagnosing multiple sclerosis. However, a more conclusive, consistent, and efficient way of diagnosing multiple sclerosis (MS) is yet to be discovered. A potential biomarker, discovered using advances in high-throughput sequencing such as nuclear magnetic resonance (NMR) spectroscopy and other "Omics"-based techniques, may make diagnosis and prognosis more reliable resulting in a more personalized and targeted treatment regime and improved outcomes. The aim of this review was to systematically search the literature for potential biomarkers from any bodily fluid that could consistently and accurately diagnose MS and/or indicate disease progression. Methods: A systematic literature review of EMBASE, PubMed (MEDLINE), The Cochrane Library, and CINAHL databases produced over a thousand potential studies. Inclusion criteria stated studies with potential biomarker outcomes for people with MS were to be included in the review. Studies were limited to those with human participants who had a clinically defined diagnosis of MS and published in English, with no limit placed on date of publication or the type of bodily fluid sampled. Results: A total of 1,805 studies were recorded from the literature search. A total of 1,760 studies were removed based on their abstract, with a further 18 removed after considering the full text. A total of 30 studies were considered relevant and had their data retrieved and analyzed. Due to the heterogeneity of focus and results from the refined studies, a narrative synthesis was favored. Conclusion: Several promising candidate biomarkers suitable for clinical application in MS have been studied. It is recommended follow-up studies with larger sample sizes be completed on several potential biomarkers.
dc.languageEnglish
dc.publisherFRONTIERS MEDIA SA
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleMetabolomic Biomarkers of Multiple Sclerosis: A Systematic Review
dc.typeJournal Article
dc.identifier.doi10.3389/fmolb.2020.574133
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.affiliation.departmentDoherty Institute
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleFrontiers in Molecular Biosciences
melbourne.source.volume7
dc.rights.licenseCC BY
melbourne.elementsid1486041
melbourne.contributor.authorde Livera, Alysha
melbourne.contributor.authorJelinek, George
melbourne.contributor.authorWeiland, Tracey
dc.identifier.eissn2296-889X
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record